Treatment with AMONDYS 45 (casimersen).
A lack of dystrophin causes muscle cells to become damaged and weakened over time.
AMONDYS 45 uses exon-skipping technology to allow the body to make a shorter form of the dystrophin protein by skipping over a specific exon on the dystrophin gene.a
aBoys treated with AMONDYS 45 showed varying levels of increased dystrophin production after 48 weeks. In an ongoing clinical study, 27 boys (median age 9 years) receiving AMONDYS 45 had an average dystrophin level of 1.74% of normal, compared to 0.76% in 16 boys who received a placebo infusion.
Amenable
a•me•na•ble
əˈmēnəb(ə)l,əˈmenəb(ə)l/
(of a thing) capable of being acted upon in a particular way; susceptible to.
“The Duchenne patient’s genetic test identified that he had a mutation that could be treated by AMONDYS 45. His doctor said he was amenable to treatment with the exon-skipping therapy.”
What is exon skipping?
Duchenne is caused by a genetic mutation in the dystrophin gene. Most commonly, one or more exons (parts of the gene) are missing, causing errors in the instructions for making dystrophin. This results in the body not being able to produce enough—or any—working dystrophin protein. The goal of exon skipping is to allow the body to make a shorter form of the dystrophin protein.a This video will show you how.
aBoys treated with AMONDYS 45 showed varying levels of increased dystrophin production after 48 weeks. In an ongoing clinical study, 27 boys (median age 9 years) receiving AMONDYS 45 had an average dystrophin level of 1.74% of normal, compared to 0.76% in 16 boys who received a placebo infusion.
How exon skipping works.
Understanding the dystrophin gene.
The dystrophin gene is made up of exons (portions of a gene) that are linked together to provide instructions for making dystrophin—a protein our muscles need to work properly. Without dystrophin, muscle cells become damaged and weaken over time.
How exons connect.
With 79 exons, the dystrophin gene is the largest in the body. Think of the exons on the dystrophin gene like toy train cars, each with a special connection that allows one car to connect to another. In order for all the cars to move together as a train, the connections between cars must match—for example, circle-to-circle and square-to-square.
When an exon is missing.
Here we can see that car 44—or exon 44—is missing. The result is that cars 43 and 45 are not able to connect because their connectors are different shapes and don’t fit together. In the dystrophin gene, this missing exon would prevent the body from being able to read the instructions for making the dystrophin protein.
Skipping over exons.
By moving certain exons—or cars—aside, we can “skip over” them to find a car with the right connector. The new train would be shorter, but the cars are connected. Just as we skipped over a train car, AMONDYS 45 is designed to skip over an exon.
The result: A shorter form of dystrophin.
AMONDYS 45 works using exon-skipping technology. Weekly infusions with AMONDYS 45 have been shown to help the body make a shorter form of the dystrophin protein.a Watch the video.
aBoys treated with AMONDYS 45 showed varying levels of increased dystrophin production after 48 weeks. In an ongoing clinical study, 27 boys (median age 9 years) receiving AMONDYS 45 had an average dystrophin level of 1.74% of normal, compared to 0.76% in 16 boys who received a placebo infusion.
Sign up to get updates
from Sarepta.
Related FAQs
Yes. AMONDYS 45 is being studied in an ongoing clinical trial. See clinical trial results.
Duchenne patients who receive AMONDYS 45 must have a genetic test that shows a mutation in the dystrophin gene that can be treated by skipping exon 45. Your child's doctor is best equipped to determine if your child’s mutation is amenable to treatment with AMONDYS 45. We’ve developed a Doctor Discussion Guide to help you start that important conversation.